Transurethral Bulking Agents — Procedure Guide, Recovery & Risks | MyMedicPlus

Transurethral bulking agent injection is a minimally invasive office or day-case procedure for stress urinary incontinence (SUI) caused by intrinsic urethral sphincter deficiency (ISD). A biocompatible material is injected into the submucosa of the proximal urethra or periurethral tissue under cystoscopic guidance, increasing coaptation of the urethral walls and improving urethral closure pressure during physical exertion. Currently licensed agents include polyacrylamide hydrogel (Bulkamid — the preferred modern agent), polydimethylsiloxane (Macroplastique), and calcium hydroxylapatite (Coaptite). Bulking agents offer a non-mesh, reversible alternative to surgical slings for appropriately selected patients, particularly those who are frail, have failed prior surgery, wish to preserve future fertility, or prefer to avoid the anaesthetic risks and recovery associated with formal surgery. The procedure does not require general anaesthesia and can be performed in an outpatient cystoscopy setting within 15-30 minutes, making it an accessible treatment option across all patient age groups. Clinical outcomes with Bulkamid have been validated in prospective multicentre registry data demonstrating sustained continence improvement at 3-5 year follow-up with a favourable safety profile. The procedure is repeatable without accumulating additional technical complexity, making it suitable for long-term management of stress urinary incontinence in appropriately selected patients who have not responded to or declined surgical mesh implantation.

Bulking agent injection is best indicated for women with stress urinary incontinence due to intrinsic urethral sphincter deficiency (ISD) — characterised by a low leak point pressure below 60 cmH2O on urodynamics — or combined ISD with urethral hypermobility who have not adequately responded to supervised pelvic floor physiotherapy for a minimum of three months. Ideal candidates include elderly or frail women in whom general anaesthesia or abdominal surgery carries significant operative risk, women who wish to avoid synthetic mesh implants following updated regulatory guidance on mesh use, those who have previously undergone failed continence surgery and present with a fixed non-mobile urethra (drain-pipe urethra) where sling procedures have lower efficacy, women wishing to preserve fertility and prefer a temporary solution, and patients requesting a low-risk initial treatment before considering formal surgery. Urodynamic confirmation of stress incontinence mechanism is recommended before proceeding to ensure optimal patient selection.

The procedure is performed in an outpatient cystoscopy suite under local anaesthesia alone — intraurethral lignocaine gel applied for 5-10 minutes, supplemented by periurethral infiltration with 1% lidocaine if needed — or light intravenous sedation for anxious patients. With the patient in the lithotomy position, a rigid or flexible cystoscope is introduced into the bladder under direct vision and the bladder inspected. The scope is partially withdrawn to the mid-urethra level. A fine-gauge injection needle is passed through the cystoscope working channel and advanced into the urethral submucosa at the 3 oclock or 9 oclock positions, or at multiple circumferential positions around the clock-face. For Bulkamid, 1-2 mL of polyacrylamide hydrogel is injected at each injection site using a slow, controlled push, creating a visible submucosal bleb. Adequate coaptation — the urethral walls meeting in the midline — is confirmed cystoscopically after each injection. Typically two to four injections of 1-2 mL each are made at a single session, totalling 3-8 mL of bulking material. The procedure takes 15-30 minutes. A voiding trial is performed before discharge to confirm satisfactory bladder emptying; patients in whom voiding is incomplete are taught clean intermittent self-catheterisation (CISC). The total procedure time including cystoscopy, infiltration, and voiding trial is approximately 30-60 minutes in total.

Immediate improvement in continence is reported by 50-70% of patients after their initial Bulkamid injection session, with complete continence achieved in approximately 25-40% of well-selected patients. Repeat injections (a second or third session at 4-6 weeks) improve cumulative response rates to 60-70% at one year. Bulkamid has demonstrated durable results with 46-55% of patients maintaining significant benefit at three to five years in prospective registry data. The procedure does not compromise future surgical options; women who do not achieve satisfactory improvement can proceed to midurethral sling surgery without increased technical difficulty. No general anaesthesia is required, procedure-related morbidity is low, and the brief recovery allows return to normal activities within 24-48 hours. For elderly women with ISD in whom surgery is not appropriate, bulking agents represent the most effective available office-based treatment option.

Temporary urinary retention requiring clean intermittent catheterisation (CIC) occurs in 10-20% of patients in the immediate post-procedural period; most cases resolve within 24-72 hours as urethral oedema subsides. Urinary tract infection occurs in 5-10% and is managed with a short antibiotic course. Urethral discomfort, mild haematuria, and frequency are common for 24-48 hours post-procedure and are self-limiting. With older agents (collagen, PTFE particles), migration to distant sites was a concern, but modern agents such as Bulkamid (polyacrylamide hydrogel) remain stable and have not demonstrated clinically significant migration in long-term studies. Urethral erosion or granuloma formation is rare with modern biocompatible agents. Agent resorption over time (particularly with collagen-based materials) is the primary cause of declining efficacy; repeat injection sessions address this. Serious complications including urethral injury or periurethral abscess are rare but reported in case series. Patient selection is key — bulking agents are significantly less effective than slings for urethral hypermobility without ISD.

Patients are observed for 1-2 hours post-procedure and discharged once they have voided satisfactorily with a post-void residual under 150 mL on bladder ultrasound. Those who cannot void are taught clean intermittent self-catheterisation and discharged with a catheter supply and a follow-up appointment within 3-5 days. Normal light activities can resume the same day or the following day. Strenuous exercise, swimming, and sexual intercourse are avoided for 2-3 weeks to allow the injected material to stabilise. A post-procedure urine culture is sent at the time of the procedure; if positive, a targeted antibiotic course is prescribed. The full therapeutic benefit of bulking agent injection typically develops over 4-6 weeks as periurethral tissue remodelling occurs around the injected material. Follow-up continence assessment is scheduled at 6-8 weeks; patients who have incomplete improvement are offered a repeat injection session. Pelvic floor physiotherapy should be continued alongside bulking agent treatment to maximise and maintain outcomes.